q********g
发帖数: 10694 | 1 观点很象这里Jenny12以前说的。从中也学习到一些分析医药股的方法。例文欣赏。
http://seekingalpha.com/article/895051-sarepta-therapeutics-loo
Sarepta Therapeutics Looks Highly Undervalued
September 28, 2012 | 37 commentsby: Sean Anderson | about: SRPT
R.S. Analytics wrote up the long case for Sarepta Therapeutics (SRPT)
earlier this month here. I agree with that thesis, and won't bore everyone
by repeating it here since R.S. did such a great job telling it already.
There are, however, a few points that I'd like to expand on.
In ... 阅读全帖 |
|
|
b*****p
发帖数: 9649 | 3 FDA tells Sarepta new drug filing for eteplirsen 'premature'
Sarepta provided an update on its discussions with the FDA regarding its
planned New Drug Application submission and confirmatory clinical study with
eteplirsen for the treatment of Duchenne muscular dystrophy. Citing recent
developments since Sarepta's last meeting with the agency, including a
failed study with a competitive product and recent natural history data in
DMD, the FDA indicated the new data raise "considerable doubt" about... 阅读全帖 |
|
g****e
发帖数: 1426 | 4 本想抽插一下，想不到成了股东。
话说一切都有可能，下10上20。其实它家的药到现在为止是最好的。只是不能提前上市
“Prosensa and Glaxo started to lose ground against Sarepta in August, after
the two companies released disappointing phase 2 trial results that didn't
measure up to Sarepta's. One particular damaging comparison was in the
production of dystrophin, a protein required for muscle growth that DMD
patients lack. Prosensa's drug showed dystrophin production in 72% of
patients receiving a continuous dose of the drug, whereas Sarepta's drug
resu... 阅读全帖 |
|
|
T*C
发帖数: 5492 | 6 Sarepta Therapeutics (SRPT) +119.4% premarket after announcing its exon-
skipping compound eteplirsen achieved a significant clinical benefit after a
36-week PhaseIIb study in the treatment of Duchenne muscular dystrophy
patients. |
|
g****e
发帖数: 1426 | 7 last minute filled:
11/15/2013
Pending CMA-Edge xxX-xxxxxx Buy
SAREPTA THERAPEUTICS INC SRPT 200 16.00 (3,200.00) |
|
|
发帖数: 1 | 9 *********************************************************
上礼拜每日盘前动能股扫描结果，周末重新再测试
一星期之内扫到的18只股票，下两周后势机会多多
*********************************************************
关键词
BGNE APVO INSM APOP XOMA CLLS VYGR VSTM PTN
SRPT PULM NLNK IMGN IMMU ALDR KURA CLVS ADAP
September 01, 2017
BeiGene Ltd. (ADR) BGNE
★ 你们谁认识王晓东？他在北京的百济神州抗肿瘤药物公司，Feb 2016 IPO @ 24，开
曼群岛注册，lofty valuation over $3B now，两个月时间从40涨到80，三波冲高做成
完形头肩顶，我考虑卖空不买账，不过得等这波BIO热潮消停些再入手。
Aptevo Therapeutics APVO
★ 一整月超卖触底的情况下，翻倍高开马上sell on news开跌，从2.... 阅读全帖 |
|
d*****r
发帖数: 2583 | 10 RNA一大早跌了80%..
http://www.businessweek.com/news/2013-09-20/prosensa-shares-plu
Bloomberg News
Prosensa Shares Plunge as Muscular Dystrophy Drug Fails in Trial
By Makiko Kitamura September 20, 2013
Prosensa Holding NV (RNA:US) plunged after the Dutch company’s experimental
muscular dystrophy drug failed to help patients walk better in a clinical
trial.
Prosensa sank 71 percent to $7 at 7:55 a.m. New York time in trading (RNA:US
) before U.S. exchanges opened. The company is based in Leiden, the
Ne... 阅读全帖 |
|
q********g
发帖数: 10694 | 11 我从AVII的时候就开始买了，与其说埋伏，不如说被套，一路买一路跌，换成srpt了3.
XX也加了不少，7.xx我在pennystock那边发贴说了，也加了，13.7x也加了一些，并且
贴了几个pump这个股的帖子，前一天还贴了一帖第二天突然早上看了吓了一跳，39.7x
出了。我跟老婆说别工作了，多生两个吧，呵呵。其中要感谢jenny12提点，让我在15.
xx的时候hold住了，本来已经达到目标位要出了。
周四和周五连跌了两天，周一估计也会再跌，但是反弹在即，因为各大机构吹这个股吹
的大家都盼着买了。目标价位between $44.50 and $47.50 per share，有人说会到100
+，不过我相信近期就是45这个顶了。这个药效果非常明显，而且这个病非常要紧。总
之对于一个药股所有的好消息都在这里了。
另外有增发的可能。
http://finviz.com/quote.ashx?t=srpt
http://seekingalpha.com/article/895051-sarepta-therapeutics-loo
好交作业了。 |
|
